IL2 and autoimmune hepatitis: In a prospective, open label phase I‐IIa study of 46 patients with a variety of autoimmune diseases [119] including patients with AIH and sclerosing cholangitis, a dose of 1million IU/day of IL‐2 was given for 5 days, followed by fortnightly injections for 6 months.